Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics
Drug Metabolism and Disposition · 2026-05 · 54 (5) · 100287
DOI: 10.1016/j.dmd.2026.100287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-05. Verfasst von Charles R Esther und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Marsico Lung Institute, University of North Carolina…. Hauptthemen laut MEDLINE: Inflammation, Respiratory Mucosa, Membrane Transport Proteins. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCRR NIH HHS, FDA HHS.
Abstract (Originalsprache)
The efficacy of inhaled drugs is significantly influenced by airway epithelial transporters that mediate their transport and distribution. Because inhaled drugs are used across diverse populations with inflammatory airway diseases, understanding factors that modulate transporter expression is crucial. Therefore, we investigated how inflammatory states, demographic factors, and airway anatomic location impact drug transporter abundance. Using quantitative targeted absolute proteomics, we measured transporter abundance in primary human bronchial epithelia (HBE) from 42 demographically diverse donors. To model distinct inflammatory environments, HBE were exposed to interleukin (IL)-1β (T-helper type [TH]1/neutrophilic inflammation) or IL-13 (TH2/eosinophilic inflammation) for 4 days, alongside baseline controls. We also measured transporter protein concentrations in small airway HBE from 5 donors to assess regional influence. In the primary set of HBE, multidrug resistance protein (MRP)1 (3.96 ± 1.64 pmol/mg protein) and peptide transporter 2 (3.12 ± 0.95 pmol/mg protein) were the most abundant transporters, and their concentrations were responsive to inflammatory signals. Specifically, IL-1β significantly reduced MRP1 (0.80-fold) and peptide transporter 2 (0.65-fold), whereas IL-13 modestly increased MRP1 (1.1-fold) but reduced peptide transporter 2 (0.73-fold) and novel organic cation transporter (OCTN)1 (0.44-fold). Several transporters present at lower abundance, including MRP4, MRP5, MRP6, and OCTN1, were also impacted by inflammation. Demographic factors also played a role, with MRP4 higher in females, and age positively correlated with MRP6 but negatively with OCTN1. Analysis of small airway-derived HBE did not show a significant impact of anatomic location on transporter abundance. Our findings demonstrate that airway inflammation and donor demographics significantly impact the protein expression of key drug transporters, highlighting dynamic factors crucial for optimizing inhaled drug delivery and efficacy. SIGNIFICANCE STATEMENT: Human airway epithelia express multiple transporters, with multidrug resistance protein 1 and peptide transporter 2 present at the highest levels. Transporter abundance is influenced by inflammation, age, and biological sex, but not by airway anatomic location. This information can guide the modeling of inhaled drug pharmacokinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: char…
- Division of Pharmacoengineering and Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
- Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina; USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Unive…
Förderung
- NIDDK NIH HHS
- NCRR NIH HHS
- FDA HHS
- Cystic Fibrosis Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases
- U.S. Department of Health and Human Services
- US Food and Drug Administration
- National Institutes of Health
Zitieren
APA
Esther, C. R., Fallon, J. K., Cholon, D. M., Boyles, S. E., Williams, A. B., Murano, H., Okuda, K., Tiley, J. B., Tan, M. L., Zhao, L., Mikami, Y., Smith, P. C., Rao, G., & Gentzsch, M. (2026). Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics. Drug Metabolism and Disposition, 54(5), 100287. https://doi.org/10.1016/j.dmd.2026.100287
Vancouver
Esther CR, Fallon JK, Cholon DM, Boyles SE, Williams AB, Murano H, et al. Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics. Drug Metabolism and Disposition. 2026;54(5):100287. doi:10.1016/j.dmd.2026.100287
BibTeX
@article{Esther2026,
author = {Esther, Charles R and Fallon, John K and Cholon, Deborah M and Boyles, Susan E and Williams, Allison B and Murano, Hiroaki and Okuda, Kenichi and Tiley, Jacqueline B and Tan, Ming-Liang and Zhao, Liang and Mikami, Yu and Smith, Philip C and Rao, Gauri and Gentzsch, Martina},
title = {Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {5},
pages = {100287},
doi = {10.1016/j.dmd.2026.100287}
}
EUVIMED